Dae Gon Ha
Stock Analyst
(3.06)
# 1,516
Out of 4,648 analysts
46
Total ratings
37.84%
Success rate
4.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $55.93 | +32.31% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $3.28 | -8.54% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $4.43 | +261.58% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $15.12 | +323.18% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $173.74 | +26.63% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $40.28 | +63.85% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $50.90 | +149.51% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $6.14 | +242.02% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $6.33 | +531.91% | 3 | Apr 3, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $9 → $17 | $3.05 | +458.29% | 2 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.51 | +190.82% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.01 | +349.44% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.73 | +858.90% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $54.00 | -53.70% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $11.38 | +40.60% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $11.75 | +2,325.53% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.70 | +441.27% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.86 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $25.13 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.24 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.55 | +674.19% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $98 | $0.77 | +12,627.27% | 2 | Oct 23, 2017 |
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $55.93
Upside: +32.31%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $3.28
Upside: -8.54%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $4.43
Upside: +261.58%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $15.12
Upside: +323.18%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $173.74
Upside: +26.63%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $40.28
Upside: +63.85%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $50.90
Upside: +149.51%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $6.14
Upside: +242.02%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $6.33
Upside: +531.91%
Editas Medicine
Sep 29, 2023
Upgrades: Buy
Price Target: $9 → $17
Current: $3.05
Upside: +458.29%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $16.51
Upside: +190.82%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $4.01
Upside: +349.44%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.73
Upside: +858.90%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $54.00
Upside: -53.70%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $11.38
Upside: +40.60%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $11.75
Upside: +2,325.53%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $3.70
Upside: +441.27%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.86
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $25.13
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.24
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.55
Upside: +674.19%
Oct 23, 2017
Maintains: Outperform
Price Target: $120 → $98
Current: $0.77
Upside: +12,627.27%